Haemonetics Corporation Elects New Board Members

Susan Bartlett Foote, associate professor and head of the Division of Health Service Research and Policy at the University of Minnesota's School of Public Health, and Pedro Granadillo, senior vice president at Eli Lilly and Company, have been appointed to the Haemonetics Corporation Board of Directors. The appointments are effective immediately, and both Foote and Granadillo will serve on the Compensation and Management Development Committee, with Granadillo also joining the Nominating and Governance Committee. Ronald A. Matricaria, Haemonetics' Chairman, praised the new board members for their exceptional strengths and diverse backgrounds, which will complement those of the existing board.

Key Takeaways:

Susan Bartlett Foote, a 20-year professor of health service research and policy, brings extensive experience in healthcare policy, regulatory, and governmental affairs to the Haemonetics Board.
Pedro Granadillo, senior vice president at Eli Lilly and Company, has a strong record of leadership in implementing award-winning human resource programs and managing a world-class global manufacturing organization.
Both Foote and Granadillo have significant industry experience, with Foote having served as president of Public Policy Partners and Granadillo holding various leadership positions at Eli Lilly, including vice president of manufacturing and human resources.
Foote serves on multiple boards, including Banner Health Systems, Urologix, Inc., and the Park Nicollet Research Institute, and participates in the Centers for Medicare and Medicaid Services' Medicare Coverage Advisory Committee.
Granadillo has been with Eli Lilly since 1970 and has held several leadership positions, including vice president of manufacturing and human resources, and currently serves on the boards of First Indiana Corporation and Purdue Research Foundation.
Both Foote and Granadillo have a strong track record of leadership and experience in the healthcare and biotechnology industries.

Statistics:

Haemonetics Corporation earns revenue from the design, manufacture, and worldwide marketing of automated blood processing systems.
The company has a global presence, addressing important medical markets in surgical blood salvage, blood component collection, plasma collection, and blood component safety.
Susan Bartlett Foote has been a professor for more than 20 years, with more than 10 years of experience in regulatory and governmental affairs.
Pedro Granadillo has held various leadership positions at Eli Lilly, including 13 years in international assignments.

Sources:

Julie Fallon, Haemonetics Corporation publicist, +1-781-356-9517, or Alt. Tel., +1-617-320-2401, fallon@haemonetics.com, mentioned in contact information.
Original Press Release from Haemonetics Corporation.